

# Nadine G Roupphael

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3598848/publications.pdf>

Version: 2024-02-01

81  
papers

20,704  
citations

136950

32  
h-index

76900

74  
g-index

88  
all docs

88  
docs citations

88  
times ranked

31813  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 403-416.	27.0	7,910
2	An mRNA Vaccine against SARS-CoV-2 – Preliminary Report. <i>New England Journal of Medicine</i> , 2020, 383, 1920-1931.	27.0	2,719
3	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 795-807.	27.0	1,398
4	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. <i>New England Journal of Medicine</i> , 2020, 383, 2427-2438.	27.0	1,242
5	Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. <i>Science</i> , 2020, 369, 1210-1220.	12.6	947
6	The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. <i>Science Immunology</i> , 2020, 5, .	11.9	772
7	Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. <i>New England Journal of Medicine</i> , 2021, 384, 80-82.	27.0	665
8	Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 2259-2261.	27.0	603
9	Infections associated with haemophagocytic syndrome. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 814-822.	9.1	496
10	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 1372-1377.	12.6	459
11	Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. <i>Cell Reports Medicine</i> , 2021, 2, 100354.	6.5	316
12	The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. <i>Lancet</i> , The, 2017, 390, 649-658.	13.7	309
13	<i>Neisseria meningitidis</i> : Biology, Microbiology, and Epidemiology. <i>Methods in Molecular Biology</i> , 2012, 799, 1-20.	0.9	280
14	Metabolic Phenotypes of Response to Vaccination in Humans. <i>Cell</i> , 2017, 169, 862-877.e17.	28.9	234
15	Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. <i>Cell Host and Microbe</i> , 2021, 29, 516-521.e3.	11.0	199
16	COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva. <i>Journal of Clinical Microbiology</i> , 2020, 59, .	3.9	193
17	Innate, T-, and B-Cell Responses in Acute Human Zika Patients. <i>Clinical Infectious Diseases</i> , 2018, 66, 1-10.	5.8	162
18	mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. <i>Cell Reports Medicine</i> , 2022, 3, 100529.	6.5	158

#	ARTICLE	IF	CITATIONS
19	The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination. <i>Cell</i> , 2021, 184, 3915-3935.e21.	28.9	133
20	Serological Responses to an Avian Influenza A/H7N9 Vaccine Mixed at the Point-of-Use With MF59 Adjuvant. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1409.	7.4	126
21	Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies. <i>Current Protocols in Immunology</i> , 2020, 131, e116.	3.6	111
22	Triplex Real-Time RT-PCR for Severe Acute Respiratory Syndrome Coronavirus 2. <i>Emerging Infectious Diseases</i> , 2020, 26, 1633-1635.	4.3	104
23	Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. <i>Vaccine</i> , 2015, 33, 5225-5234.	3.8	92
24	Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 17957-17964.	7.1	57
25	The Future of Flu: A Review of the Human Challenge Model and Systems Biology for Advancement of Influenza Vaccinology. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 107.	3.9	53
26	Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS) Tj ETQq0 0 0 rgBT /Overlock 1 <i>Lancet Infectious Diseases</i> , The, 2022, 22, 636-648.	9.1	52
27	Acceptability of an inactivated influenza vaccine delivered by microneedle patch: Results from a phase I clinical trial of safety, reactogenicity, and immunogenicity. <i>Vaccine</i> , 2020, 38, 7175-7181.	3.8	44
28	<i>Streptococcus infantis</i> , <i>Streptococcus mitis</i> , and <i>Streptococcus oralis</i> Strains With Highly Similar cps5 Loci and Antigenic Relatedness to Serotype 5 Pneumococci. <i>Frontiers in Microbiology</i> , 2018, 9, 3199.	3.5	42
29	Systems Vaccinology for a Live Attenuated Tularemia Vaccine Reveals Unique Transcriptional Signatures That Predict Humoral and Cellular Immune Responses. <i>Vaccines</i> , 2020, 8, 4.	4.4	40
30	<i>Streptococcus mitis</i> Expressing Pneumococcal Serotype 1 Capsule. <i>Scientific Reports</i> , 2018, 8, 17959.	3.3	37
31	Broadly Reactive Human CD8 T Cells that Recognize an Epitope Conserved between VZV, HSV and EBV. <i>PLoS Pathogens</i> , 2014, 10, e1004008.	4.7	36
32	Dissolvable Microneedle Patches to Enable Increased Access to Vaccines against SARS-CoV-2 and Future Pandemic Outbreaks. <i>Vaccines</i> , 2021, 9, 320.	4.4	36
33	Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults. <i>Journal of Immunology</i> , 2017, 199, 604-612.	0.8	33
34	The Effect of Anticoagulants, Temperature, and Time on the Human Plasma Metabolome and Lipidome from Healthy Donors as Determined by Liquid Chromatography-Mass Spectrometry. <i>Biomolecules</i> , 2019, 9, 200.	4.0	33
35	Hepatitis B reverse seroconversion in HIV-positive patients: case series and review of the literature. <i>Aids</i> , 2007, 21, 771-774.	2.2	31
36	Tularemia vaccine: Safety, reactogenicity, take-skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial. <i>Vaccine</i> , 2017, 35, 4730-4737.	3.8	30

#	ARTICLE	IF	CITATIONS
37	The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein. <i>Virology</i> , 2021, 559, 1-9.	2.4	29
38	Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients: Prolonged RNA Detection in Whole Blood. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy352.	0.9	26
39	<i>Streptococcus pneumoniae</i> colonization after introduction of 13-valent pneumococcal conjugate vaccine for US adults 65 years of age and older, 2015–2016. <i>Vaccine</i> , 2019, 37, 1094-1100.	3.8	23
40	Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease. <i>Clinical Infectious Diseases</i> , 2021, 72, 1127-1137.	5.8	23
41	Phase Ib Trial To Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of Filiciclovir (MBX-400, Cyclopropavir) in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	18
42	Racial and Ethnic Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States. <i>Vaccines</i> , 2022, 10, 290.	4.4	18
43	Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. <i>Vaccine</i> , 2017, 35, 1675-1682.	3.8	17
44	Pre-Existing Dengue Immunity Drives a DENV-Biased Plasmablast Response in ZIKV-Infected Patient. <i>Viruses</i> , 2019, 11, 19.	3.3	16
45	Persistence of Varicella-Zoster Virus-Specific Plasma Cells in Adult Human Bone Marrow following Childhood Vaccination. <i>Journal of Virology</i> , 2020, 94, .	3.4	15
46	Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial. <i>Npj Vaccines</i> , 2021, 6, 89.	6.0	15
47	Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. <i>Vaccine</i> , 2018, 36, 606-614.	3.8	14
48	Willingness to Participate in Vaccine-Related Clinical Trials among Older Adults. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1743.	2.6	13
49	A Painful Thorn in the Foot: A Case of Eumycetoma. <i>American Journal of the Medical Sciences</i> , 2007, 334, 142-144.	1.1	12
50	Evaluation of Serum Bactericidal Antibody Assays for <i>Haemophilus influenzae</i> Serotype a. <i>Vaccine Journal</i> , 2011, 18, 243-247.	3.1	12
51	Retrospective Study of Cryptococcal Meningitis With Elevated Minimum Inhibitory Concentration to Fluconazole in Immunocompromised Patients. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw076.	0.9	12
52	Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old. <i>Journal of Infectious Diseases</i> , 2015, 212, 552-561.	4.0	11
53	Diagnostic Importance of Hyphae on Heart Valve Tissue in Histoplasma Endocarditis and Treatment With Isavuconazole. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx241.	0.9	10
54	Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine. <i>Journal of Infectious Diseases</i> , 2018, 217, 1055-1059.	4.0	8

#	ARTICLE	IF	CITATIONS
55	Fecal Microbiota Transplantation Donor Screening Updates and Research Gaps for Solid Organ Transplant Recipients. <i>Journal of Clinical Microbiology</i> , 2021, , JCM0016121.	3.9	7
56	Microneedle patch for immunization of immunocompromised hosts. <i>Oncotarget</i> , 2017, 8, 93311-93312.	1.8	7
57	The Role of Systems Vaccinology in Understanding the Immune Defects to Vaccination in Solid Organ Transplant Recipients. <i>Frontiers in Immunology</i> , 2020, 11, 582201.	4.8	7
58	Rapid Detection and Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Variant in a Returning Traveler. <i>Clinical Infectious Diseases</i> , 2022, 75, e350-e353.	5.8	7
59	Skin Ulcers Misdiagnosed as Pyoderma Gangrenosum. <i>New England Journal of Medicine</i> , 2003, 348, 1064-1066.	27.0	6
60	Development and optimization of a Zika virus antibody-dependent cell-mediated cytotoxicity (ADCC) assay. <i>Journal of Immunological Methods</i> , 2021, 488, 112900.	1.4	6
61	Proteomic Analysis of Human Immune Responses to Live-Attenuated Tularemia Vaccine. <i>Vaccines</i> , 2020, 8, 413.	4.4	5
62	Retinopathy and Systemic Disease Morbidity in Severe COVID-19. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 743-750.	1.8	5
63	EVITA Dengue: a cluster-randomized controlled trial to Evaluate the efficacy of Wolbachia-Infected Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil. <i>Trials</i> , 2022, 23, 185.	1.6	5
64	Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 Exposure. <i>Vaccines</i> , 2020, 8, 348.	4.4	4
65	Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine. <i>Vaccines</i> , 2020, 8, 69.	4.4	4
66	Staphylococcus simulans: A rare uropathogen. <i>IDCases</i> , 2021, 25, e01202.	0.9	4
67	Longitudinal analysis of human humoral responses after vaccination with a live attenuated V. cholerae vaccine. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009743.	3.0	4
68	Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera. <i>Microbiology Spectrum</i> , 2021, 9, e0045821.	3.0	3
69	Effect of Concomitant Antibiotic and Vaccine Administration on Serologic Responses to Rotavirus Vaccine. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 479-482.	1.3	2
70	A Retrospective Chart Review on the Role of Suppressive Therapy in the Management of Spinal Infections Involving Hardware. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa253.	0.9	2
71	Swimming with the Pigs: A Case of Severe Soft Tissue Infection during a Caribbean Vacation. <i>Case Reports in Infectious Diseases</i> , 2018, 2018, 1-3.	0.5	1
72	Occupational Exposure to the Ugandan Research Strain (MR766) of Zika Virus. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz420.	0.9	1

#	ARTICLE	IF	CITATIONS
73	Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine. <i>Vaccines</i> , 2020, 8, 126.	4.4	1
74	Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials. <i>PLoS Pathogens</i> , 2021, 17, e1010016.	4.7	1
75	Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum. <i>Journal of Infectious Diseases</i> , 2022, 226, 1771-1780.	4.0	1
76	Nonsurgical Antimicrobial Prophylaxis. , 0, , 791-796.		0
77	Nonsurgical antimicrobial prophylaxis. , 0, , 746-751.		0
78	2314. Burden of Respiratory Syncytial Virus (RSV) Infection Among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF). <i>Open Forum Infectious Diseases</i> , 2019, 6, S793-S794.	0.9	0
79	2739. Comparison of Hemagglutination Antibody Inhibition (HAI) Titers Following Influenza Vaccination by Birth Cohort and Repeated Influenza Vaccination History. <i>Open Forum Infectious Diseases</i> , 2019, 6, S964-S964.	0.9	0
80	Reply letter to "Fatal meningococemia due to <i>Neisseria meningitidis</i> serogroup Y in a vaccinated child receiving eculizumab". <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1-2.	3.3	0
81	COVID-19 Vaccine Trials (and Tribulations): How to improve the process of clinical trials in a pandemic. <i>Clinical Infectious Diseases</i> , 2022, , .	5.8	0